Oncology CROs in China

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Chinese CDMO providing pharmaceutical development and manufacturing services from drug discovery to commercialization, known as a long-term supplier to major pharmaceutical companies including Pfizer.

Shanghai campus of BioDuro-Sundia providing integrated discovery and development services including medicinal chemistry, DMPK, biology, and preclinical development for global biotech.

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Labcorp Drug Development's Chinese laboratory providing preclinical safety assessment, bioanalytical services, and clinical trial support for NMPA regulatory submissions.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Shanghai-based preclinical CRO providing in vivo pharmacology, toxicology, DMPK, and bioanalytical services with specialized PDX platforms for oncology drug development.

Chinese operations of Frontage Laboratories providing bioanalytical services, ADME/PK studies, and analytical chemistry from GLP-compliant laboratories in Shanghai and Suzhou.

Shanghai-based specialised clinical CRO providing full clinical development services in China and APAC with expertise in navigating NMPA regulatory pathways for multinational pharmaceutical companies.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Chinese pharmaceutical company providing contract research and clinical development services for pharmaceutical companies seeking NMPA approvals in China.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

PPD's Chinese clinical operations providing Phase I-IV clinical development, regulatory strategy, and site management for multinational and domestic pharmaceutical companies in Greater China.

Integrated pharmaceutical R&D service platform offering drug discovery, preclinical, clinical, and commercial manufacturing services to biotech and pharma companies globally.

Chinese CDMO providing API development and manufacturing services including custom synthesis, process development, and commercial-scale production from multiple GMP-certified facilities.

One of China's earliest chemistry-focused CROs offering integrated drug discovery, DMPK, and pharmaceutical development services globally.

Chinese CRO and CDMO providing drug discovery chemistry, DMPK, analytical services, and clinical trial manufacturing from Shanghai and Chengdu operations.

China's largest independent CRO providing comprehensive clinical development services from preclinical through post-marketing with operations across China, Asia, and globally.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Global biologics CDMO providing end-to-end solutions for biologics drug development and manufacturing including monoclonal antibodies, bispecific antibodies, ADCs, and cell and gene therapies.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.

WuXi AppTec's pharmaceutical development and manufacturing arm providing API process development, formulation development, analytical services, and GMP manufacturing from China and US facilities.